Cargando…

Ocular Inserts of Voriconazole-Loaded Proniosomal Gels: Formulation, Evaluation and Microbiological Studies

BACKGROUND: Voriconazole (VRC) is a triazole broad spectrum antifungal drug, used in the management of versatile fungal infections, particularly fungal keratitis. The obligatory use of niosomal delivery of VRC may reduce the frequency of dosing intervals resulting from its short biological half time...

Descripción completa

Detalles Bibliográficos
Autores principales: El-Emam, Ghada Ahmed, Girgis, Germeen N S, El-Sokkary, Mohamed M Adel, El-Azeem Soliman, Osama Abd, Abd El Gawad, Abd El Gawad H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567543/
https://www.ncbi.nlm.nih.gov/pubmed/33116503
http://dx.doi.org/10.2147/IJN.S268208
_version_ 1783596345913769984
author El-Emam, Ghada Ahmed
Girgis, Germeen N S
El-Sokkary, Mohamed M Adel
El-Azeem Soliman, Osama Abd
Abd El Gawad, Abd El Gawad H
author_facet El-Emam, Ghada Ahmed
Girgis, Germeen N S
El-Sokkary, Mohamed M Adel
El-Azeem Soliman, Osama Abd
Abd El Gawad, Abd El Gawad H
author_sort El-Emam, Ghada Ahmed
collection PubMed
description BACKGROUND: Voriconazole (VRC) is a triazole broad spectrum antifungal drug, used in the management of versatile fungal infections, particularly fungal keratitis. The obligatory use of niosomal delivery of VRC may reduce the frequency of dosing intervals resulting from its short biological half time and consequently improve patient compliance. METHODS: VRC loaded proniosomes (VRC-PNs) were set by the coacervation technique and completely characterized. The developed formula was comprehensively assessed concerning in- vitro release behavior, kinetic investigation, and its conflict against refrigerated and room temperature conditions. A selected noisomal formula was incorporated into ocusert (VRC-PNs Ocu) formulated by 1% w/w hydroxypropyl methyl cellulose HPMC and 0.1% w/w carbopol (940). Eventually, in vitro antifungal activity against Candida albicans and Aspergillus nidulans was assessed by the cup diffusion method. RESULTS: The optimized VRC-PNs (Pluronic F127: cholesterol weight ratio 1:1 w/w) exhibited the highest entrapment efficiency (87.4±2.55%) with a spherical shape, proper size in nano range and a suitable Zeta potential of 209.7±8.13 nm and −33.5±1.85 mV, respectively. Assurance of drug encapsulation in nanovesicles was accomplished by several means such as attenuated total reflection Fourier-transform infrared spectroscopy, differential scanning calorimetry in addition to powder X-ray diffraction investigations. It displayed a biphasic in vitro release pattern and after 6 months of storage at a refrigerated temperature, the optimized formula preserved its stability. VRC-PNs Ocu proved a very highly significant antifungal activity matched with the free drug or nanosuspension which was extra assured by comparing its mean inhibition zone with that of 5% natamycin market eye drops. CONCLUSION: In conclusion, VRC-PNs Ocu could be considered as a promising stable sustained release topical ocular nanoparticulate system for the management of fungal infections.
format Online
Article
Text
id pubmed-7567543
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-75675432020-10-27 Ocular Inserts of Voriconazole-Loaded Proniosomal Gels: Formulation, Evaluation and Microbiological Studies El-Emam, Ghada Ahmed Girgis, Germeen N S El-Sokkary, Mohamed M Adel El-Azeem Soliman, Osama Abd Abd El Gawad, Abd El Gawad H Int J Nanomedicine Original Research BACKGROUND: Voriconazole (VRC) is a triazole broad spectrum antifungal drug, used in the management of versatile fungal infections, particularly fungal keratitis. The obligatory use of niosomal delivery of VRC may reduce the frequency of dosing intervals resulting from its short biological half time and consequently improve patient compliance. METHODS: VRC loaded proniosomes (VRC-PNs) were set by the coacervation technique and completely characterized. The developed formula was comprehensively assessed concerning in- vitro release behavior, kinetic investigation, and its conflict against refrigerated and room temperature conditions. A selected noisomal formula was incorporated into ocusert (VRC-PNs Ocu) formulated by 1% w/w hydroxypropyl methyl cellulose HPMC and 0.1% w/w carbopol (940). Eventually, in vitro antifungal activity against Candida albicans and Aspergillus nidulans was assessed by the cup diffusion method. RESULTS: The optimized VRC-PNs (Pluronic F127: cholesterol weight ratio 1:1 w/w) exhibited the highest entrapment efficiency (87.4±2.55%) with a spherical shape, proper size in nano range and a suitable Zeta potential of 209.7±8.13 nm and −33.5±1.85 mV, respectively. Assurance of drug encapsulation in nanovesicles was accomplished by several means such as attenuated total reflection Fourier-transform infrared spectroscopy, differential scanning calorimetry in addition to powder X-ray diffraction investigations. It displayed a biphasic in vitro release pattern and after 6 months of storage at a refrigerated temperature, the optimized formula preserved its stability. VRC-PNs Ocu proved a very highly significant antifungal activity matched with the free drug or nanosuspension which was extra assured by comparing its mean inhibition zone with that of 5% natamycin market eye drops. CONCLUSION: In conclusion, VRC-PNs Ocu could be considered as a promising stable sustained release topical ocular nanoparticulate system for the management of fungal infections. Dove 2020-10-12 /pmc/articles/PMC7567543/ /pubmed/33116503 http://dx.doi.org/10.2147/IJN.S268208 Text en © 2020 El-Emam et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
El-Emam, Ghada Ahmed
Girgis, Germeen N S
El-Sokkary, Mohamed M Adel
El-Azeem Soliman, Osama Abd
Abd El Gawad, Abd El Gawad H
Ocular Inserts of Voriconazole-Loaded Proniosomal Gels: Formulation, Evaluation and Microbiological Studies
title Ocular Inserts of Voriconazole-Loaded Proniosomal Gels: Formulation, Evaluation and Microbiological Studies
title_full Ocular Inserts of Voriconazole-Loaded Proniosomal Gels: Formulation, Evaluation and Microbiological Studies
title_fullStr Ocular Inserts of Voriconazole-Loaded Proniosomal Gels: Formulation, Evaluation and Microbiological Studies
title_full_unstemmed Ocular Inserts of Voriconazole-Loaded Proniosomal Gels: Formulation, Evaluation and Microbiological Studies
title_short Ocular Inserts of Voriconazole-Loaded Proniosomal Gels: Formulation, Evaluation and Microbiological Studies
title_sort ocular inserts of voriconazole-loaded proniosomal gels: formulation, evaluation and microbiological studies
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567543/
https://www.ncbi.nlm.nih.gov/pubmed/33116503
http://dx.doi.org/10.2147/IJN.S268208
work_keys_str_mv AT elemamghadaahmed ocularinsertsofvoriconazoleloadedproniosomalgelsformulationevaluationandmicrobiologicalstudies
AT girgisgermeenns ocularinsertsofvoriconazoleloadedproniosomalgelsformulationevaluationandmicrobiologicalstudies
AT elsokkarymohamedmadel ocularinsertsofvoriconazoleloadedproniosomalgelsformulationevaluationandmicrobiologicalstudies
AT elazeemsolimanosamaabd ocularinsertsofvoriconazoleloadedproniosomalgelsformulationevaluationandmicrobiologicalstudies
AT abdelgawadabdelgawadh ocularinsertsofvoriconazoleloadedproniosomalgelsformulationevaluationandmicrobiologicalstudies